Cabaletta Bio Q3 2024 Earnings Report
Key Takeaways
Cabaletta Bio reported its Q3 2024 financial results, highlighting the ongoing clinical execution with 40 U.S. clinical sites actively recruiting patients for the RESET clinical trial program for CABA-201. The company is preparing to present clinical data from the RESET-Myositis™, RESET-SLE™ and RESET-SSc™ trials at ACR Convergence 2024. Cabaletta expects its cash, cash equivalents and short-term investments to fund its operating plan into the first half of 2026.
Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented at ACR Convergence 2024.
16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients.
Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201.
Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International.
Cabaletta Bio
Cabaletta Bio
Forward Guidance
Cabaletta Bio expects that its cash, cash equivalents and short-term investments as of September 30, 2024, will enable it to fund its operating plan into the first half of 2026.